New injection aims to restore strength in seniors with sarcopenia
NCT ID NCT07668180
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests an experimental drug called IN-207907 in 100 elderly people with sarcopenia, a condition causing muscle loss and weakness. Participants receive three doses of the drug or a placebo by IV every four weeks. The main goal is to see if the drug improves physical performance, like walking speed and balance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IN-207907 injection
- What this could lead to
- If successful, this could point toward a treatment to improve mobility and reduce frailty in older adults with muscle loss.
- What could go wrong
- This is an early Phase 2 trial with only 100 participants, so results may not apply to everyone. The drug may not improve physical function more than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOPENIA IN ELDERLY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could Pre-Exercise training boost strength in aging muscles?
- Can a daily pill help older adults regain strength?
- Virtual reality workouts may help seniors recover faster in the hospital
- Can a seaweed cake help fight Age-Related muscle loss?
- Cuff trick may help aging muscles grow without heavy lifting
- Can adding body-awareness exercises to a proven fall-prevention program keep seniors steadier on their feet?